þ
|
QUARTERLY REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934.
|
¨
|
TRANSACTION REPORT PURSUANT TO
SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF
1934
|
New
York
|
11-0853640
|
|
(State
or other Jurisdiction of
|
(I.R.S.
Employer Identification No.)
|
|
incorporation
or organization)
|
616
N. North Court, Suite 120
|
||
Palatine,
Illinois
|
60067
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
Large
accelerated filer o
|
Accelerated
filer þ
|
|
Non-accelerated
filer o
|
Smaller
reporting company o
|
Page
No.
|
|||
Item
1.
|
Financial
Statements (Unaudited)
|
||
Consolidated
Balance Sheets
March
31, 2009 and December 31, 2008
|
1
|
||
Consolidated
Statements of Operations
Three
months ended March 31, 2009 and March 31, 2008
|
2
|
||
Consolidated
Statement of Stockholders’ Equity
Three
months ended March 31, 2009
|
3
|
||
Consolidated
Statements of Cash Flows
Three
months ended March 31, 2009
|
4
|
||
Notes
to Consolidated Financial Statements
|
5
|
||
Item
2.
|
Management's
Discussion and Analysis of Financial Condition and Results of
Operations
|
11
|
|
Item
4.
|
Controls
and Procedures
|
15
|
|
PART
II. OTHER INFORMATION
|
|||
Item
1A.
|
Risk
Factors Relating to the Company
|
16
|
|
Item
6.
|
Exhibits
|
17
|
|
Signatures
|
18
|
March 31,
2009
|
December 31,
2008
|
|||||||
Assets
|
||||||||
Current
assets
|
||||||||
Cash
and cash equivalents
|
$ | 37,013 | $ | 30,398 | ||||
Short
term investments
|
- | 5,039 | ||||||
Collaboration
revenue receivable
|
117 | 3,529 | ||||||
Prepaid
expense and other current assets
|
231 | 431 | ||||||
Deferred
income taxes
|
3,323 | 2,491 | ||||||
Total
current assets
|
40,684 | 41,888 | ||||||
Non-current
assets
|
||||||||
Property,
plant and equipment, net
|
1,069 | 1,073 | ||||||
Total
assets
|
$ | 41,753 | $ | 42,961 | ||||
Liabilities
and Stockholders’ Equity
|
||||||||
Current
liabilities
|
||||||||
Accounts
payable
|
$ | - | $ | 382 | ||||
Accrued
expenses
|
1,052 | 883 | ||||||
Deferred
program fee revenue
|
3,368 | 4,632 | ||||||
Total
liabilities
|
4,420 | 5,897 | ||||||
Commitments
and contingencies (Note 10)
|
||||||||
Stockholders’
equity
|
||||||||
Common stock - $.01 par value; 650,000 shares authorized;
42,740
and 42,723 shares issued and outstanding at
March
31, 2009 and December 31, 2008, respectively
|
427 | 427 | ||||||
Additional
paid-in capital
|
345,569 | 344,023 | ||||||
Accumulated
deficit
|
(308,663 | ) | (307,386 | ) | ||||
Total
stockholders’ equity
|
37,333 | 37,064 | ||||||
Total
liabilities and stockholders’ equity
|
$ | 41,753 | $ | 42,961 |
Three Months
Ended March 31,
|
||||||||
2009
|
2008
|
|||||||
Revenue
|
||||||||
Program
fee revenue
|
$ | 1,263 | $ | 13,707 | ||||
Collaboration
revenue
|
117 | 3,377 | ||||||
Total
revenue
|
1,380 | 17,084 | ||||||
Operating
expenses
|
||||||||
Research
and development expenses
|
1,129 | 4,082 | ||||||
Marketing,
general and administrative expenses
|
2,448 | 870 | ||||||
Total
operating expenses
|
3,577 | 4,952 | ||||||
Operating
(loss) income
|
(2,197 | ) | 12,132 | |||||
Other
income – interest, net
|
69 | 297 | ||||||
(Loss)
income before income tax
|
(2,128 | ) | 12,429 | |||||
Income
tax (benefit) expense
|
(851 | ) | 4,980 | |||||
Net
(loss) income
|
$ | (1,277 | ) | $ | 7,449 | |||
(Loss)
earnings per share
|
||||||||
Basic
|
$ | (0.03 | ) | $ | 0.16 | |||
Diluted
|
$ | (0.03 | ) | $ | 0.15 | |||
Weighted
average shares used in computation
|
||||||||
Basic
|
45,708 | 45,657 | ||||||
Diluted
|
45,708 | 49,439 |
Common
Stock
$0.01 Par
Value -
Shares
|
Common
Stock
$0.01 Par
Value -
Amount
|
Additional
Paid-in
Capital
|
Accumulated
Deficit
|
Total
|
||||||||||||||||
Balance
at December 31, 2008
|
42,723 | $ | 427 | $ | 344,023 | $ | (307,386 | ) | $ | 37,064 | ||||||||||
Net
loss
|
- | - | - | (1,277 | ) | (1,277 | ) | |||||||||||||
Stock
based compensation
|
- | - | 1,546 | - | 1,546 | |||||||||||||||
Exercise
of warrants
|
17 | - | - | - | - | |||||||||||||||
Balance
at March 31, 2009
|
42,740 | $ | 427 | $ | 345,569 | $ | (308,663 | ) | $ | 37,333 |
2009
|
2008
|
|||||||
Cash
flows from operating activities
|
||||||||
Net
(loss) income
|
$ | (1,277 | ) | $ | 7,449 | |||
Adjustments
to reconcile net (loss) income to net cash provided by (used in) operating
activities
|
||||||||
Depreciation
and amortization
|
32 | 42 | ||||||
Deferred
income taxes
|
(832 | ) | 4,980 | |||||
Non-cash
stock compensation expense
|
1,546 | 121 | ||||||
Impairment
reserve against fixed assets
|
- | (51 | ) | |||||
Changes
in assets and liabilities
|
||||||||
Collaboration
revenue receivable
|
3,413 | (400 | ) | |||||
Prepaid
expenses and other current assets
|
198 | 232 | ||||||
Accounts
payable
|
(382 | ) | - | |||||
Accrued
expenses
|
168 | (24 | ) | |||||
Deferred
program fee revenue
|
(1,263 | ) | (13,708 | ) | ||||
Net
cash provided by (used in) operating activities
|
1,603 | (1,359 | ) | |||||
Cash
flows from investing activities
|
||||||||
Purchase
of investments
|
- | (4,000 | ) | |||||
Investment
maturities
|
5,039 | - | ||||||
Capital
expenditures
|
(27 | ) | (7 | ) | ||||
Net
cash provided by (used in) investing activities
|
5,012 | (4,007 | ) | |||||
Increase
(decrease) in cash and cash equivalents
|
6,615 | (5,366 | ) | |||||
Cash
and cash equivalents at beginning of period
|
30,398 | 31,368 | ||||||
Cash
and cash equivalents at end of period
|
$ | 37,013 | $ | 26,002 | ||||
Cash
paid for income taxes
|
$ | 74 | $ | - |
1.
|
Warrants
to purchase 38,000 shares of common stock were exercised at exercise price
of $3.40 per share in a series of cashless exercise transactions resulting
in the issuance of 17,000 shares of common
stock.
|
1.
|
Fixed
assets having a net book value of $51,000 were disposed under the
impairment reserve.
|
|
·
|
intravenous
injection of dissolved tablets or
capsules;
|
|
·
|
nasal
snorting of crushed tablets or capsules;
and
|
|
·
|
intentional
swallowing of excess quantities of tablets or
capsules.
|
Mar
31,
|
Dec
31,
|
|||||||
2009
|
2008
|
|||||||
Payroll,
bonus, taxes and benefits
|
$ | 326 | $ | 77 | ||||
Legal
fees
|
43 | 35 | ||||||
Audit
and tax professional services
|
59 | 89 | ||||||
Franchise
taxes
|
232 | 144 | ||||||
Property
taxes
|
40 | 39 | ||||||
State
income taxes
|
- | 94 | ||||||
Clinical,
regulatory, trademarks, and patent services
|
107 | 217 | ||||||
Other
fees and services
|
245 | 188 | ||||||
$ | 1,052 | $ | 883 |
2009
|
||||
Dividend
yield
|
0.00 | % | ||
Risk-free
interest rate
|
1.50 | % | ||
Volatility
|
107 | % | ||
Forfeitures
|
0.00 | % | ||
Expected
life of option
|
3.4
years
|
|||
Grant
date fair value
|
$ | 5.69 |
2009
|
||||
Dividend
yield
|
0.0 | % | ||
Average
risk-free interest rate used
|
2.77 | % | ||
Average
volatility used
|
124 | % | ||
Forfeitures
|
0.0 | % | ||
Expected
life of option
|
10
years
|
|||
Weighted
average grant date fair value
|
$ | 6.28 |
|
Three Months Ended
|
|||||||
|
March 31,
|
|||||||
(in
thousands, except per share data)
|
2009
|
2008
|
||||||
Basic
(loss) earnings per share
|
||||||||
Numerator:
|
||||||||
Net
(loss) income allocable to common shareholder
|
$ | (1,277 | ) | $ | 7,449 | |||
Denominator:
|
||||||||
Common
shares (weighted)
|
42,736 | 42,707 | ||||||
Vested
restricted stock units (weighted)
|
2,972 | 2,950 | ||||||
Weighted
average shares used in computing basic (loss) earnings per share allocable
to common
shareholder
|
45,708 | 45,657 | ||||||
Basic
(loss) earnings per share allocable to common
shareholder
|
$ | (0.03 | ) | $ | 0.16 | |||
Diluted
(loss) earnings per share
|
||||||||
Denominator:
|
||||||||
Common
shares (weighted)
|
42,736 | 42,707 | ||||||
Vested
restricted stock units (weighted)
|
2,972 | 2,950 | ||||||
Stock
options
|
- | 1,448 | ||||||
Common
stock warrants
|
- | 2,334 | ||||||
Weighted
average shares used in computing diluted (loss) earnings per share
allocable to common shareholder
|
45,708 | 49,439 | ||||||
Diluted (loss) earnings per share allocable to common
shareholder
|
$ | (0.03 | ) | $ | 0.15 | |||
Excluded
potentially dilutive securities:
|
||||||||
Common
stock issuable (see #1 below):
|
||||||||
Stock
options (vested and nonvested)
|
3,138 | 86 | ||||||
Nonvested
restricted stock units
|
46 | - | ||||||
Common
stock warrants
|
3,870 | 47 | ||||||
Total
excluded dilutive common stock equivalents
|
7,054 | 133 |
|
·
|
intravenous
injection of dissolved tablets or
capsules;
|
|
·
|
nasal
snorting of crushed tablets or capsules;
and
|
|
·
|
intentional
swallowing of excess quantities of tablets or
capsules.
|
March
31,
|
Change
|
|||||||||||||||
($ in thousands):
|
2009
|
2008
|
Dollars
|
%
|
||||||||||||
Revenue
|
||||||||||||||||
Program
fee revenue
|
$ | 1,263 | $ | 13,707 | $ | (12,444 | ) | (91 | ) % | |||||||
Collaboration
revenue
|
117 | 3,377 | (3,260 | ) | (97 | ) | ||||||||||
Total
revenue
|
1,380 | 17,084 | (15,704 | ) | (92 | ) | ||||||||||
Operating
expenses
|
||||||||||||||||
Research
and development expenses
|
1,129 | 4,082 | (2,953 | ) | (72 | ) | ||||||||||
Marketing,
general and administrative expenses
|
2,448 | 870 | 1,578 | 181 | ||||||||||||
Total
operating expenses
|
3,577 | 4,952 | (1,375 | ) | - | |||||||||||
Operating
(loss) income
|
(2,197 | ) | 12,132 | (14,329 | ) | (118 | ) | |||||||||
Other
income - interest, net
|
69 | 297 | (228 | ) | (77 | ) | ||||||||||
(Loss)
income before income tax
|
(2,128 | ) | 12,429 | (14,557 | ) | (117 | ) | |||||||||
Income
tax (benefit) expense
|
(851 | ) | 4,980 | 5,831 | (117 | ) | ||||||||||
Net
(loss) income
|
$ | (1,277 | ) | $ | 7,449 | $ | (8,726 | ) | (117 | ) % |
Payments due by period
|
||||||||||||||||||||
(in thousands)
|
Total
|
Less than 1
year
|
1-3 years
|
3-5 years
|
More than 5
years
|
|||||||||||||||
Operating
leases
|
$ | 31 | $ | 23 | $ | 8 | — | — | ||||||||||||
Clinical
studies
|
37 | 37 | — | — | — | |||||||||||||||
Employment
agreements
|
855 | 735 | 120 | — | — | |||||||||||||||
Total
|
$ | 923 | $ | 795 | $ | 128 | — | — |
10.1
|
Employment
Agreement dated as of March 23, 2009 between Acura Pharmaceuticals, Inc.
and Garth Boehm.
|
31.1
|
Certification
of Periodic Report by Chief Executive Officer pursuant to Rule 13a-14 and
15d-14 of the Securities Exchange Act of
1934.
|
31.2
|
Certification
of Periodic Report by Chief Financial Officer pursuant to Rule 13a-14 and
15d-14 of the Securities Exchange Act of
1934.
|
32.1
|
Certification
of Periodic Report by the Chief Executive Officer and Chief Financial
Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
906 of the Sarbanes-Oxley Act of
2002.
|
April
29, 2009
|
ACURA
PHARMACEUTICALS, INC.
|
/s/ Andrew D. Reddick
|
|
Andrew
D. Reddick
|
|
President
& Chief Executive Officer
|
|
/s/ Peter A. Clemens
|
|
Peter
A. Clemens
|
|
Senior
VP & Chief Financial
Officer
|